A Galactosidase-Responsive "Trojan Horse" for the Selective Targeting of Folate Receptor-Positive Tumor Cells

Licence to Kill: A β‐galactosidase‐responsive molecular “Trojan horse” was designed to selectively kill folate receptor‐positive tumor cells. The recognition of the folate membrane receptor is followed by the internalization and the subsequent enzymatic activation of the targeting assembly to releas...

Full description

Saved in:
Bibliographic Details
Published in:ChemMedChem 2011-06, Vol.6 (6), p.1006-1010
Main Authors: Thomas, Mickaël, Clarhaut, Jonathan, Strale, Pierre-Olivier, Tranoy-Opalinski, Isabelle, Roche, Joëlle, Papot, Sébastien
Format: Article
Language:English
Subjects:
Animals
anticancer agents
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - pharmacology
beta-Galactosidase - metabolism
Cell Line, Tumor
Cell Proliferation - drug effects
Doxorubicin - administration & dosage
Doxorubicin - pharmacology
drug delivery
Drug Delivery Systems
folate receptors
Folate Receptors, GPI-Anchored - metabolism
glycosides
Humans
Ligands
Neoplasms - drug therapy
prodrugs
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Licence to Kill: A β‐galactosidase‐responsive molecular “Trojan horse” was designed to selectively kill folate receptor‐positive tumor cells. The recognition of the folate membrane receptor is followed by the internalization and the subsequent enzymatic activation of the targeting assembly to release the cytotoxic agent in a stringently controlled fashion exclusively inside the targeted cells.
ISSN:1860-7179
1860-7187
DOI:10.1002/cmdc.201100114